Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | KDM4B | O94953 | 1/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064636 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL17009466 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| Kinetin SCHEMBL29829493 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| Kinetin SCHEMBL15705 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL4400404 | 0.78 | UTS2R (0.55) | TSHRCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL16146154 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL17009428 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL29830290 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL20119562 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2ATSHRHIF1A | |
| SCHEMBL16147171 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ATSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | SMN1; SMN2 106/4885MEN1 2209/4885KMT2A 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.